PUBLISHER: The Business Research Company | PRODUCT CODE: 1751024
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751024
Idiopathic intracranial hypertension (IIH) treatment involves medical and surgical approaches aimed at lowering intracranial pressure and preventing complications such as vision loss. These treatments may include lifestyle modifications, such as weight loss, medications such as acetazolamide to reduce fluid buildup, and surgical interventions, including shunt placement or optic nerve sheath fenestration in more severe cases.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main treatment types for idiopathic intracranial hypertension include medications, surgeries, and therapies. Medications are used to reduce cerebrospinal fluid production, relieve symptoms such as headaches and visual disturbances, and manage underlying conditions. These medications are typically administered orally or intrathecally. Diagnostic methods for IIH include neuroimaging, lumbar puncture, and visual field tests, and treatments are generally provided in hospitals, specialized clinics, or ambulatory surgical centers.
The idiopathic intracranial hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides idiopathic intracranial hypertension treatment market statistics, including the idiopathic intracranial hypertension treatment industry's global market size, regional shares, competitors with a idiopathic intracranial hypertension treatment market share, detailed idiopathic intracranial hypertension treatment market segments, market trends and opportunities, and any further data you may need to thrive in the idiopathic intracranial hypertension treatment industry. This idiopathic intracranial hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The idiopathic intracranial hypertension treatment market size has grown strongly in recent years. It will grow from$1.38 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to several factors, including the rising prevalence of obesity, increased healthcare spending, a growing emphasis on minimally invasive surgical techniques, the increasing prevalence of comorbid conditions, and a higher demand for advanced ophthalmologic diagnostic tools.
The idiopathic intracranial hypertension treatment market size is expected to see strong growth in the next few years. It will grow to$1.91 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the growing adoption of digital health solutions, the rise in lifestyle-related disorders, increased use of telemedicine, greater availability of advanced diagnostic tools, and a growing demand for personalized medicine. Key trends in the forecast period include the use of AI-driven diagnostic tools, the development of targeted therapies, advancements in non-invasive imaging techniques, the introduction of new weight management medications, and the creation of customizable shunt devices.
The growing prevalence of obesity is expected to drive the expansion of the idiopathic intracranial hypertension (IIH) treatment market in the coming years. Obesity is a medical condition characterized by excessive body fat, which can harm overall health. The rise in obesity is largely attributed to increasingly sedentary lifestyles and the consumption of calorie-dense processed foods. Obesity contributes to increased intracranial pressure by promoting the overproduction of cerebrospinal fluid and impairing its absorption, which plays a key role in the development of idiopathic intracranial hypertension. For instance, according to a 2024 report from the Office for Health Improvement and Disparities, a UK government department, 64.0% of adults aged 18 and older in England were classified as overweight or obese between 2022 and 2023. This figure is nearly the same as the 63.8% reported for the 2021 to 2022 period. Therefore, the rising obesity rates are significantly driving the growth of the idiopathic intracranial hypertension treatment market.
Leading companies in the idiopathic intracranial hypertension treatment market are focusing on developing innovative therapies aimed at managing intracranial pressure and alleviating associated symptoms. These therapies aim to improve patient outcomes through advanced drug delivery systems and targeted treatment approaches, thereby enhancing overall care and quality of life. For example, in November 2022, Invex Therapeutics, an Australia-based biopharmaceutical company, received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) to begin the Phase III IIH EVOLVE clinical trial for Presendin (sustained-release exenatide) in the treatment of idiopathic intracranial hypertension (IIH). This approval, along with clearance from the New Zealand Health and Disability Ethics Committee, allows Invex to conduct the trial with 240 newly diagnosed IIH patients at up to 40 global clinical sites, aiming to improve treatment outcomes for this neurological condition.
In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for $12 billion. This acquisition enhances Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a novel antipsychotic with a unique mechanism of action and a promising efficacy and safety profile. The acquisition aligns with Bristol Myers Squibb's long-term growth strategy and strengthens its ability to address unmet needs in neurodegenerative conditions. Karuna Therapeutics Inc. is a US-based biopharmaceutical company that focuses on developing therapies for neurological disorders.
Major players in the idiopathic intracranial hypertension treatment market are Siemens AG, Medtronic plc, Mayo Clinic, Becton Dickinson and Company, Philips Healthcare, GE HealthCare Technologies Inc., Teva Pharmaceuticals, Boston Scientific Corporation, Henry schein, Sun Pharmaceutical Industries, Zydus LifeSciences, Topcon Corporation, Natus Medical Incorporated, Canon Medical Systems Corporation, Carl Zeiss Meditec AG, Optopol Technology, Strides Pharma, NIDEK Co., Haag-Streit AG, Invex Therapeutics, and Metrovision.
North America was the largest region in the idiopathic intracranial hypertension treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in idiopathic intracranial hypertension treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the idiopathic intracranial hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The idiopathic intracranial hypertension treatment market consists of revenues earned by entities by providing services such as diagnostic imaging services, nutritional counseling, optic nerve sheath fenestration procedures, ophthalmologic evaluations, and visual field monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The idiopathic intracranial hypertension treatment market also includes sales of shunt systems, surgical instruments, intracranial pressure monitoring devices, and optical coherence tomography (OCT). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Idiopathic Intracranial Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on idiopathic intracranial hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for idiopathic intracranial hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic intracranial hypertension treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.